Optain Health provides an integrated teleophthalmology screening platform utilizing an FDA-cleared robotic camera for rapid, undilated imaging at the point of care. This system allows any staff member to capture images for specialist grading of conditions like diabetic retinopathy, streamlining workflow and improving patient adherence. The platform securely integrates with existing EHR systems to deliver actionable, ICD-10-coded reports directly into clinical dashboards.
Funding
$12M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Early detection of eye diseases and cardiovascular disease (CVD) often relies on specialized equipment and expertise, leading to delayed diagnoses and potential vision loss or cardiovascular events. Traditional screening methods can be invasive, costly, and not easily accessible, particularly in underserved communities.
Solution
Optain Health offers an AI-powered retinal imaging platform that enables non-invasive, real-time detection of eye diseases like glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD), as well as indicators of cardiovascular risk. The platform consists of the Resolve portable automatic fundus camera and the Eyetelligence Assure software suite. The AI algorithms analyze retinal images to identify subtle indicators of disease, providing clinicians with rapid risk assessment reports. This integrated solution facilitates early intervention, improves patient outcomes, and democratizes access to specialized disease screening.
Target Audience
The primary target audience includes ophthalmologists, optometrists, primary care physicians, and other healthcare providers seeking to improve early disease detection and management, as well as insurers and pharmaceutical companies interested in population health screening and clinical trial optimization.
Features
- AI-enabled software (Eyetelligence Assure) analyzes retinal images for glaucoma, diabetic retinopathy, AMD, and CVD risk
- Resolve portable automatic fundus camera offers fully automatic eye detection, focus, and adjustment for ease of use
- Clinically validated AI algorithms trained on over 1,000,000 retinal images for high accuracy (up to 95%)
- Local AWS deployment option for enhanced data privacy, security, and regulatory compliance
- Instant reporting capabilities to facilitate diagnosis, treatment, and referrals
- Cloud connectivity for secure access and sharing of retinal images, enhancing collaboration
- Integration with existing fundus cameras or available as a complete turnkey solution
- AI algorithms analyze microvasculature in retinal images to generate heatmaps indicating cardiovascular risk levels